The estimated Net Worth of Paul Averback is at least $11 Milion dollars as of 29 October 2018. Paul Averback owns over 1,687,600 units of Nymox Pharmaceutical Corp stock worth over $4,328,790 and over the last 6 years he sold NYMX stock worth over $4,394,000. In addition, he makes $2,318,000 as Chairman of the Board, President oraz Chief Executive Officer at Nymox Pharmaceutical Corp.
Sign up
Paul Averback NYMX stock SEC Form 4 insiders trading
Paul has made over 2 trades of the Nymox Pharmaceutical Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,687,600 units of NYMX stock worth $4,219,000 on 29 October 2018.
The largest trade he's ever made was selling 1,687,600 units of Nymox Pharmaceutical Corp stock on 29 October 2018 worth over $4,219,000. On average, Paul trades about 893,800 units every 2 days since 2018. As of 29 October 2018 he still owns at least 21,643,948 units of Nymox Pharmaceutical Corp stock.
You can see the complete history of Paul Averback stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Averback biography
Dr. Paul Averback, M.D., D.A.B.P., is the Chairman of the Board, President, Chief Executive Officer of Nymox Pharmaceutical Corp. President and Director since September 1995 and Chairman since June of 2001, is the founder of Nymox and the inventor of much of its initial technology. Prior to founding Nymox, Dr. Averback served as President of Nymox’s predecessor, DMS Pharmaceuticals Inc. He received his M.D. in 1975 and taught pathology at universities, including Cambridge University, England (1977-1980), during which time he initiated his research on Alzheimer’s disease. He has practiced medicine in numerous institutions as well as in private practice. Dr. Averback has published extensively in the scientific and medical literature.
What is the salary of Paul Averback?
As the Chairman of the Board, President oraz Chief Executive Officer of Nymox Pharmaceutical Corp, the total compensation of Paul Averback at Nymox Pharmaceutical Corp is $2,318,000. There are no executives at Nymox Pharmaceutical Corp getting paid more.
How old is Paul Averback?
Paul Averback is 69, he's been the Chairman of the Board, President oraz Chief Executive Officer of Nymox Pharmaceutical Corp since 2006. There are 2 older and 6 younger executives at Nymox Pharmaceutical Corp. The oldest executive at Nymox Pharmaceutical Corp is James Robinson, 84, who is the Independent Director.
What's Paul Averback's mailing address?
Paul's mailing address filed with the SEC is 9900 Boul Cavendish, Saint-Laurent, QC H4M 2V2, Canada.
Insiders trading at Nymox Pharmaceutical Corp
Over the last 9 years, insiders at Nymox Pharmaceutical Corp have traded over $4,394,000 worth of Nymox Pharmaceutical Corp stock and bought 2,534,915 units worth $5,846,809 . The most active insiders traders include James George Robinson, Paul Averback oraz Erik Danielsen. On average, Nymox Pharmaceutical Corp executives and independent directors trade stock every 27 days with the average trade being worth of $9,606. The most recent stock trade was executed by James George Robinson on 2 May 2022, trading 1,151,515 units of NYMX stock currently worth $1,900,000.
What does Nymox Pharmaceutical Corp do?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
What does Nymox Pharmaceutical Corp's logo look like?
Complete history of Paul Averback stock trades at Nymox Pharmaceutical Corp
Nymox Pharmaceutical Corp executives and stock owners
Nymox Pharmaceutical Corp executives and other stock owners filed with the SEC include:
-
Paul Averback,
Chairman of the Board, President, Chief Executive Officer -
Erik Danielsen,
Chief Financial Officer -
Erik Danielsen,
CFO & Controller -
Randall Lanham,
General Counsel, Director -
Randall J. Lanham Esq., J.D.,
Gen. Counsel, Sec., COO & Director -
James Robinson,
Independent Director -
David Morse,
Independent Director -
Richard Cutler,
Independent Director -
Lin Dodd,
QA and Compliance Mang. -
Dr. Paul Averback DABP, M.D.,
Founder, Chairman, CEO & Pres